The global preimplantation genetic testing market is projected to reach USD 1.2 Billion by 2028 from USD 0.7 Billion in 2023, at a CAGR of 11.4% during the forecast period. The growth of this market is majorly driven by the rising number of fertility clinics and IVF centers and a boost in public-private investments in the development of novel diagnostic techniques. However, unfavorable government regulations and healthcare reforms for IVF procedures restrain the growth of the preimplantation genetic testing market.
The next generation sequencing segment accounted for the highest market share in the preimplantation genetic testing market, by technology, during the forecast period.
Based on the type segment, the preimplantation genetic testing market is categorized into PCR, NGS, FISH, CGH, and SNP. The ability to sequence DNA has opened up abundant application avenues for NGS technologies in infertility treatment. NGS offers various advantages such as reduced cost, better ability to detect an embryo with differing results (mosaicism), and enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments.
Aneuploidy application segment accounted for the highest CAGR during the forecast period.
Based on application, the preimplantation genetic testing market is segmented into aneuploidy, structural chromosomal abnormalities, single gene disorders, X-linked disorders, HLA typing, and gender identification. The use of preimplantation genetic screening for aneuploidy detection increases the chance of an embryo implantation, decreases the miscarriage rate, and reduces the chance of having a child with a chromosome abnormality. These advantages are driving the demand for preimplantation genetic testing for detecting aneuploidy.
The Asia Pacific segment accounted for the highest growth rate in the preimplantation genetic testing systems market, by region, during the forecast period.
Based on the region, the global preimplantation genetic testing market is categorized into North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific is expected to witness a high growth rate during the forecast period. As a result of the rapid economic growth in the emerging countries in Asia-Pacific, the disposable income levels in the region’s countries such as China and India have witnessed a notable increase in the last decade which holds massive potential for the Asia Pacific preimplantation genetic testing market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (50%), Tier 2 (33%), and Tier 3 (17%)
- By Designation: C-level (17%), Director-level (50%), and Others (33%)
- By Region: North America (34%), Europe (35%), Asia- Pacific (26%), and Rest of the World (5%)
Prominent companies include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), The Cooper Companies, Inc. (US), Abbott (US), Takara Bio Inc. (Japan), Qiagen (Germany), Vitrolife (Sweden), Oxford Nanopore Technologies Plc (UK), Oxford Gene Technology IP Limited (UK), Yikon Genomics (China), Shiva Scientific Company (India), Nanjing Superyears Gene Technology Co. Ltd. (China), Medicover Genetics (Germany), Medgenome (India), Fulgent Genetics (US), Invicta Genetics (Poland), Genea Limited (Australia), Scigene Corporation (US), Bioarray S.L. (Spain), Unimed Biotech (Shanghai) Co. Ltd. (China), Genemind Biosciences Co. Ltd. (China), Berry Genomics (China), and Bangkok Genomics Innovation (Thailand).
Research Coverage
This research report categorizes the preimplantation genetic testing market by procedure type (preimplantation genetic screening, and preimplantation genetic diagnosis), by technology (next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, single-nucleotide polymorphism), by product and service (reagents and consumables, instruments, and software and services), by application (aneuploidy, structural chromosomal abnormalities, single gene disorders, x-linked disorders, HLA typing, and gender identification), by type of cycle (fresh non-donor, frozen non-donor, fresh donor, and frozen donor), by end-user (fertility clinics, hospitals, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the preimplantation genetic testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the preimplantation genetic testing market. Competitive analysis of upcoming startups in the preimplantation genetic testing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall preimplantation genetic testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (declining rate of fertility worldwide, the rise of fertility tourism in emerging economies, increasing number of fertility clinics and IVF centers, increasing public-private investments in the development of novel diagnostic techniques, high risk of chromosomal abnormalities with advancing maternal age), restraints (high procedural cost in preimplantation genetic testing, and unfavorable government regulation and healthcare reforms for IVF procedures), opportunities (improving healthcare infrastructure and rising medical tourism in emerging economies, and Use of fertility treatment options by single parents and same-sex couples), and challenges (socio-ethical concerns surrounding preimplantation genetic testing, and procedural limitation of preimplantation genetic testing with advancing age) influencing the growth of the preimplantation genetic testing market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the preimplantation genetic testing market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the preimplantation genetic testing market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the preimplantation genetic testing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Agilent Technologies, Inc. (US), among others in the preimplantation genetic testing market strategies.
Table of Contents
Executive Summary
Companies Mentioned
- Abbott
- Agilent Technologies, Inc.
- Bangkok Genomics Innovation
- Berry Genomics
- Bioarray S.L.
- Fulgent Genetics
- Genea Limited
- Genemind Biosciences Co. Ltd.
- Illumina, Inc.
- Invicta Genetics
- Medgenome
- Medicover Genetics
- Nanjing Superyears Gene Technology Co. Ltd.
- Oxford Gene Technology IP Limited
- Oxford Nanopore Technologies PLC
- Qiagen
- Revvity
- Sciegene Corporation
- Shiva Scientific Company
- Takara Bio Inc.
- The Cooper Companies, Inc.
- Thermo Fisher Scientific Inc.
- Unimed Biotech (Shanghai) Co. Ltd.
- Vitrolife
- Yikon Genomics
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 238 |
| Published | October 2023 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value ( USD | $ 0.7 Billion |
| Forecasted Market Value ( USD | $ 1.2 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
